Madrid-Miller A, García-Jiménez Y, Moreno-Ruiz LA

Idioma: Inglés [English version]
Referencias bibliográficas: 15
Paginas: s35-39
Archivo PDF: 177.84 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AH et al. An EAPCI expert consensus document on ischemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Euro heart J. 2020; 41 (37): 3504-3520. doi: 10.4244/EIJY20M07_01.

2. Hansen B, Holtzman JN, Juszczynski C, Khan N, Kaur G, Varma B et al. Ischemia with no obstructive arteries (INOCA): a review of the prevalence, diagnosis and management. Curr Probl Cardiol. 2022; 48 (1): 101420. doi: 10.1016/j.cpcardiol.2022.101420.

3. Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL, Camici PG, Chilian WM et al. Ischemia and no obstructive coronary artery disease (INOCA) developing evidence-based therapies and research agenda for the next decade. Circulation. 2017; 135 (11): 1075-1092. doi: 10.1161/CIRCULATIONAHA.116.024534.

4. Kenkre TS, Malhotra P, Johnson BD, Handberg EM, Thompson DV, Marroquin OC et al. Ten-year mortality in the WISE study (Women's Ischemia Syndrome Evaluation). Circ Cardiovasc Qual Outcomes. 2017; 10 (12): e003863. doi: 10.1161/CIRCOUTCOMES.116.003863.

5. Berge CA, Eskerud I, Almeland EB, Larsen TH, Pedersen ER, Rotevatn S et al. Relationship between hypertension and non-obstructive coronary artery disease in chronic coronary syndrome (the NORIC registry). PLoS One. 2022; 17 (1): e0262290. doi: 10.1371/journal.pone.0262290.

6. Eskerud I, Gerdts E, Larsen TH, Lonnebakken MT. Left ventricular hypertrophy contributes to Myocardial Ischemia in Non-obstructive Coronary Artery Disease (the MicroCAD study). Int J Cardiol. 2019; 286: 1-6. doi: 10.1016/j.ijcard.2019.03.059.

7. Padro T, Manfrini O, Bugiardini R, Canty J, Cenko E, De Luca G et al. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'. Cardiovasc Res. 2020; 116 (4): 741-755. doi: 10.1093/cvr/cvaa003.

8. Lonnebakken MT, Eskerud I, Larsen TH, Midtbo HB, Kokorina MV, Gerdts E. Impact of aortic stiffness on myocardial ischaemia in non-obstructive coronary artery disease. Open Heart. 2019; 6 (1): e000981. doi: 10.1136/openhrt-2018-000981.

9. Mehilli J, Presbitero P. Coronary artery disease and acute coronary syndrome in women. Heart. 2020; 106 (7): 487-492. doi: 10.1136/heartjnl-2019-315555.

10. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019; 139 (18): e891-e908. doi: 10.1161/CIR.0000000000000670.

11. Mygind ND, Michelsen MM, Pena A, Frestad D, Dose N, Aziz A et al. Coronary microvascular function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study. J Am Heart Assoc. 2016; 5 (3): e003064. doi: 10.1161/JAHA.115.003064.

12. Nishimiya K, Suda A, Fukui K, Hao K, Takahashi J, Matsumoto Y et al. Prognostic links between OCT-delineated coronary morphologies and coronary functional abnormalities in patients with INOCA. JACC Cardiovasc Intervent. 2021; 14 (6): 606-618. doi: 10.1016/j.jcin.2020.12.025.

13. Pauly DF, Johnson BD, Anderson RD, Handberg EM, Smith KM, Cooper-DeHoff RM et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011; 162 (4): 678-684. doi: 10.1016/j.ahj.2011.07.011.

14. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000; 36 (2): 220-225. doi: 10.1161/01.HYP.36.2.220.

15. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjold AM, Gard A et al. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with non-obstructive coronary artery disease. Circulation. 2017; 135 (16): 1481-1489. doi: 10.1161/CIRCULATIONAHA.116.026336.